Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis

  • Jae Yeong Cho (Department of Cardiovascular Medicine, Chonnam National University Hospital, Chonnam National University Medical School) ;
  • Dong-Hyuk Cho (Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Jong-Chan Youn (Division of Cardiology, Department of Internal Medicine, Catholic Research Institute for Intractable Cardiovascular Disease, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Darae Kim (Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Sang Min Park (Department of Cardiology, Nowon Eulji Medical Center, Eulji University) ;
  • Mi-Hyang Jung (Division of Cardiology, Department of Internal Medicine, Catholic Research Institute for Intractable Cardiovascular Disease, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Junho Hyun (Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jimi Choi (Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Hyun-Jai Cho (Department of Internal Medicine, Seoul National University Hospital) ;
  • Seong-Mi Park (Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Jin-Oh Choi (Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Wook-Jin Chung (Division of Cardiology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine) ;
  • Byung-Su Yoo (Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine) ;
  • Seok-Min Kang (Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine) ;
  • Committee of Clinical Practice Guidelines, Korean Society of Heart Failure (Korean Society of Heart Failure)
  • Received : 2023.02.09
  • Accepted : 2023.04.04
  • Published : 2023.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

The Korean Society of Heart Failure guidelines aim to provide physicians with evidence-based recommendations for diagnosing and managing patients with heart failure (HF). In Korea, the prevalence of HF has been rapidly increasing in the last 10 years. HF has recently been classified into HF with reduced ejection fraction (EF), HF with mildly reduced EF, and HF with preserved EF (HFpEF). Moreover, the availability of newer therapeutic agents has led to an increased emphasis on the appropriate diagnosis of HFpEF. Accordingly, this part of the guidelines will mainly cover the definition, epidemiology, and diagnosis of HF.

Keywords

Acknowledgement

This article has been published jointly, with consent, in both Korean Circulation Journal and International Journal of Heart Failure. Also, the final version of this guideline was endorsed by Korean Society of Cardiology, Korean Society of Lipid and Atherosclerosis, Korean Association of Clinical Cardiology, Korean Society of Hypertension, Korean Society of Heart Failure, Korean Society of Echocardiography, Korean Society of Interventional Cardiology, Korean Heart Rhythm Society, and Korean Society of CardioMetabolic Syndrome.

References

  1. Kim KJ, Cho HJ, Kim MS, et al. Focused update of 2016 Korean Society of Heart Failure guidelines for the management of chronic heart failure. Int J Heart Fail 2019;1:4-24. https://doi.org/10.36628/ijhf.2019.0002
  2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. https://doi.org/10.1093/eurheartj/ehab368
  3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: Executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:1757-80. https://doi.org/10.1016/j.jacc.2021.12.011
  4. Cho DH, Yoo BS. Current prevalence, incidence, and outcomes of heart failure with preserved ejection fraction. Heart Fail Clin 2021;17:315-26. https://doi.org/10.1016/j.hfc.2021.03.002
  5. Shim CY. Heart failure with preserved ejection fraction: the major unmet need in cardiology. Korean Circ J 2020;50:1051-61. https://doi.org/10.4070/kcj.2020.0338
  6. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455-62. https://doi.org/10.1093/eurheartj/ehv464
  7. Solomon SD, McMurray JJ, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-20. https://doi.org/10.1056/NEJMoa1908655
  8. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018;20:1230-9. https://doi.org/10.1002/ejhf.1149
  9. Lam CS, Solomon SD. Delivering therapeutic efficacy across the ejection fraction spectrum of heart failure. Circulation 2022;146:1193-5.  https://doi.org/10.1161/CIRCULATIONAHA.122.062022
  10. Cho JH, Choe WS, Cho HJ, et al. Comparison of characteristics and 3-year outcomes in patients with acute heart failure with preserved, mid-range, and reduced ejection fraction. Circ J 2019;83:347-56. https://doi.org/10.1253/circj.CJ-18-0543
  11. Arrigo M, Huber LC, Winnik S, et al. Right ventricular failure: pathophysiology, diagnosis and treatment. Card Fail Rev 2019;5:140-6. https://doi.org/10.15420/cfr.2019.15.2
  12. Lee HH, Cho SM, Lee H, et al. Korea heart disease fact sheet 2020: analysis of nationwide data. Korean Circ J 2021;51:495-503. https://doi.org/10.4070/kcj.2021.0097
  13. Kang SM. Key role of the Korean Society of Heart Failure: moving towards a global and individualized approach. Int J Heart Fail 2022;4:136-8. https://doi.org/10.36628/ijhf.2022.0014
  14. Yingchoncharoen T, Wu TC, Choi DJ, Ong TK, Liew HB, Cho MC. Economic burden of heart failure in Asian countries with different healthcare systems. Korean Circ J 2021;51:681-93. https://doi.org/10.4070/kcj.2021.0029
  15. Chung H, Sohn IS. Economic burden of heart failure in Asian countries based on real-world data. Korean Circ J 2021;51:694-5. https://doi.org/10.4070/kcj.2021.0197
  16. Cho SM, Lee H, Kim HC. Sex- and age-specific trends in cardiovascular health in Korea, 2007-2018. Korean Circ J 2021;51:922-35. https://doi.org/10.4070/kcj.2021.0211
  17. Cho DH, Lee CJ, Son JW, Choi J, Hwang J, Yoo BS. Temporal trends in heart failure over 11 years in the aging Korean population: a retrospective study using the national health insurance database. PLoS One 2022;17:e0279541.
  18. Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000;139:72-7. https://doi.org/10.1016/S0002-8703(00)90311-9
  19. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292.
  20. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013;6:606-19. https://doi.org/10.1161/HHF.0b013e318291329a
  21. Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail 2021;3:224-36. https://doi.org/10.36628/ijhf.2021.0023
  22. Kim MS. The long journey to obtaining the epidemiological data of heart failure in Korea. Int J Heart Fail 2021;3:221-3. https://doi.org/10.36628/ijhf.2021.0036
  23. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-72. https://doi.org/10.1161/01.CIR.0000039105.49749.6F
  24. Lee JH, Lim NK, Cho MC, Park HY. Epidemiology of heart failure in Korea: present and future. Korean Circ J 2016;46:658-64. https://doi.org/10.4070/kcj.2016.46.5.658
  25. Choi DJ, Han S, Jeon ES, et al. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the Korean Heart Failure Registry. Korean Circ J 2011;41:363-71. https://doi.org/10.4070/kcj.2011.41.7.363
  26. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF). Korean Circ J 2017;47:341-53. https://doi.org/10.4070/kcj.2016.0419
  27. Lee HY, Oh BH. Paradigm shifts of heart failure therapy: do we need another paradigm? Int J Heart Fail 2020;2:145-56. https://doi.org/10.36628/ijhf.2020.0010
  28. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:1-207, iii. https://doi.org/10.3310/hta13320
  29. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011;124:2865-73. https://doi.org/10.1161/CIRCULATIONAHA.111.019216
  30. Lee KS, Noh J, Park SM, et al. Evaluation and management of patients with diabetes and heart failure: a Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Int J Heart Fail 2023;5:1-20. https://doi.org/10.36628/ijhf.2022.0028
  31. Gohar A, Rutten FH, den Ruijter H, et al. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. Eur J Heart Fail 2019;21:1219-27. https://doi.org/10.1002/ejhf.1495
  32. Galderisi M, Cosyns B, Edvardsen T, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301-10. https://doi.org/10.1093/ehjci/jex244
  33. Wettersten N. Biomarkers in acute heart failure: diagnosis, prognosis, and treatment. Int J Heart Fail 2021;3:81-105. https://doi.org/10.36628/ijhf.2020.0036
  34. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6. https://doi.org/10.1016/j.abb.2006.03.028
  35. Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today Ther Strateg 2012;9:e131-9. https://doi.org/10.1016/j.ddstr.2013.11.002
  36. Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol 2019;73:1264-72. https://doi.org/10.1016/j.jacc.2019.01.018
  37. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66-74. https://doi.org/10.1001/jama.2013.7588
  38. Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013;62:1365-72. https://doi.org/10.1016/j.jacc.2013.05.069
  39. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537-41. https://doi.org/10.1016/j.ejheart.2005.01.022
  40. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail 2011;17:729-34. https://doi.org/10.1016/j.cardfail.2011.04.013
  41. Januzzi JL Jr, Chen-Tournoux AA, Christenson RH, et al. N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study. J Am Coll Cardiol 2018;71:1191-200. https://doi.org/10.1016/j.jacc.2018.01.021
  42. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76. https://doi.org/10.1016/j.jacc.2010.02.025
  43. Yoo BS, Kim WJ, Jung HS, et al. The clinical experiences of B-type natriuretic peptide blood concentrations for diagnosis in congestive heart failure: the single hospital experience based on the large clinical database. Korean Circ J 2004;34:684-92. https://doi.org/10.4070/kcj.2004.34.7.684
  44. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39. https://doi.org/10.1016/j.ejheart.2008.07.014
  45. Taub PR, Daniels LB, Maisel AS. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart Fail Clin 2009;5:169-75. https://doi.org/10.1016/j.hfc.2008.11.009
  46. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.  https://doi.org/10.1161/01.CIR.0000054164.99881.00
  47. Lee DS, Stitt A, Austin PC, et al. Prediction of heart failure mortality in emergent care: a cohort study. Ann Intern Med 2012;156:767-75, W-261, W-262. https://doi.org/10.7326/0003-4819-156-11-201206050-00003
  48. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-41. https://doi.org/10.1016/j.jacc.2003.09.044
  49. Kang SH, Park JJ, Choi DJ, et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart 2015;101:1881-8. https://doi.org/10.1136/heartjnl-2015-307782
  50. Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2016;68:2425-36. https://doi.org/10.1016/j.jacc.2016.09.931
  51. Weiner RB, Baggish AL, Chen-Tournoux A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 2013;15:342-51. https://doi.org/10.1093/eurjhf/hfs180
  52. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017;318:713-20. https://doi.org/10.1001/jama.2017.10565
  53. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care 2009;15:392-7. https://doi.org/10.1097/MCC.0b013e3283307a4e
  54. Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 2008;101:231-7. https://doi.org/10.1016/j.amjcard.2007.07.066
  55. Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 2020;22:350-61. https://doi.org/10.1002/ejhf.1631
  56. Lee J, Kim EJ. ST2 as a biomarker to show the preventive effect of exercise in myocardial injury by doxorubicin? Int J Heart Fail 2021;3:117-20. https://doi.org/10.36628/ijhf.2021.0003
  57. Hu SS, Kong LZ, Gao RL, et al. Outline of the report on cardiovascular disease in China, 2010. Biomed Environ Sci 2012;25:251-6.
  58. Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail 2017;5:280-6. https://doi.org/10.1016/j.jchf.2016.09.010
  59. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24. https://doi.org/10.1016/j.jacc.2006.03.061
  60. Imran TF, Shin HJ, Mathenge N, et al. Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population. Am J Cardiol 2017;119:57-64. https://doi.org/10.1016/j.amjcard.2016.09.019
  61. Park JJ, Choi DJ, Yoon CH, et al. Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). Am J Cardiol 2014;113:511-7. https://doi.org/10.1016/j.amjcard.2013.10.022
  62. Zairis MN, Tsiaousis GZ, Georgilas AT, et al. Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol 2010;141:284-90. https://doi.org/10.1016/j.ijcard.2008.12.017
  63. Cho DH, Son JW, Lee CJ, et al. Prognostic value of short-term follow-up of multiple biomarkers after discharge in hospitalized patients with acute heart failure (POSTBIO-HF): rationale and study design. Int J Heart Fail 2022;4:110-6. https://doi.org/10.36628/ijhf.2022.0005
  64. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010;122:1387-95. https://doi.org/10.1161/CIRCULATIONAHA.109.928846
  65. Bouabdallaoui N, Claggett B, Zile MR, et al. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 2018;20:1701-9. https://doi.org/10.1002/ejhf.1301
  66. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
  67. Park JJ, Park JB, Park JH, Cho GY. Global longitudinal strain to predict mortality in patients with acute heart failure. J Am Coll Cardiol 2018;71:1947-57. https://doi.org/10.1016/j.jacc.2018.02.064
  68. Yoon YE, Hong YJ, Kim HK, et al. 2014 Korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the Korean Society of Cardiology and the Korean Society of Radiology. Korean Circ J 2014;44:359-85. https://doi.org/10.4070/kcj.2014.44.6.359
  69. Sugeng L, Mor-Avi V, Weinert L, et al. Multimodality comparison of quantitative volumetric analysis of the right ventricle. JACC Cardiovasc Imaging 2010;3:10-8. https://doi.org/10.1016/j.jcmg.2009.09.017
  70. Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement--executive summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J 2009;30:278-89. https://doi.org/10.1093/eurheartj/ehn492
  71. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-77. https://doi.org/10.1093/eurheartj/ehz425
  72. Valle-Munoz A, Estornell-Erill J, Soriano-Navarro CJ, et al. Late gadolinium enhancement-cardiovascular magnetic resonance identifies coronary artery disease as the aetiology of left ventricular dysfunction in acute new-onset congestive heart failure. Eur J Echocardiogr 2009;10:968-74. https://doi.org/10.1093/ejechocard/jep115
  73. Hamilton-Craig C, Strugnell WE, Raffel OC, Porto I, Walters DL, Slaughter RE. CT angiography with cardiac MRI: non-invasive functional and anatomical assessment for the etiology in newly diagnosed heart failure. Int J Cardiovasc Imaging 2012;28:1111-22. https://doi.org/10.1007/s10554-011-9926-y
  74. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26:1461-74. https://doi.org/10.1093/eurheartj/ehi258
  75. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:2156-64. https://doi.org/10.1016/S0735-1097(02)02602-5
  76. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77. https://doi.org/10.1161/CIRCULATIONAHA.109.851352
  77. Gao P, Yee R, Gula L, et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging 2012;5:448-56. https://doi.org/10.1161/CIRCIMAGING.111.971549
  78. Puntmann VO, Carr-White G, Jabbour A, et al. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. JACC Cardiovasc Imaging 2016;9:40-50. https://doi.org/10.1016/j.jcmg.2015.12.001
  79. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018;72:3158-76. https://doi.org/10.1016/j.jacc.2018.09.072
  80. Seferovic PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:553-76. https://doi.org/10.1002/ejhf.1461
  81. Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014;35:2733-79. https://doi.org/10.1093/eurheartj/ehu284
  82. Lee HY, Jeon ES, Kang SM, Kim JJ. Initial report of the Korean Organ Transplant Registry (KOTRY): heart transplantation. Korean Circ J 2017;47:868-76.  https://doi.org/10.4070/kcj.2016.0403
  83. Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J Card Fail 2018;24:281-302. https://doi.org/10.1016/j.cardfail.2018.03.004
  84. Park HY. Hereditary dilated cardiomyopathy: recent advances in genetic diagnostics. Korean Circ J 2017;47:291-8. https://doi.org/10.4070/kcj.2016.0017
  85. Tayal U, Ware JS, Lakdawala NK, Heymans S, Prasad SK. Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know. Eur Heart J 2021;42:2384-96. https://doi.org/10.1093/eurheartj/ehab286
  86. Yogasundaram H, Alhumaid W, Dzwiniel T, Christian S, Oudit GY. Cardiomyopathies and genetic testing in heart failure: role in defining phenotype-targeted approaches and management. Can J Cardiol 2021;37:547-59. https://doi.org/10.1016/j.cjca.2021.01.016
  87. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200. https://doi.org/10.1093/eurheartj/ehw128
  88. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136:e137-61. https://doi.org/10.1161/CIR.0000000000000509
  89. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation 2017;135:825-38. https://doi.org/10.1161/CIRCULATIONAHA.116.024822
  90. Ha JW, Andersen OS, Smiseth OA. Diastolic stress test: invasive and noninvasive testing. JACC Cardiovasc Imaging 2020;13:272-82. https://doi.org/10.1016/j.jcmg.2019.01.037
  91. Shim CY. Stress testing in heart failure with preserved ejection fraction. Heart Fail Clin 2021;17:435-45. https://doi.org/10.1016/j.hfc.2021.02.007
  92. Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861-70. https://doi.org/10.1161/CIRCULATIONAHA.118.034646
  93. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:391-412. https://doi.org/10.1002/ejhf.1741